JP2017522348A5 - - Google Patents

Download PDF

Info

Publication number
JP2017522348A5
JP2017522348A5 JP2017505221A JP2017505221A JP2017522348A5 JP 2017522348 A5 JP2017522348 A5 JP 2017522348A5 JP 2017505221 A JP2017505221 A JP 2017505221A JP 2017505221 A JP2017505221 A JP 2017505221A JP 2017522348 A5 JP2017522348 A5 JP 2017522348A5
Authority
JP
Japan
Prior art keywords
group
conh
formula
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017505221A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522348A (ja
JP6599976B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/067504 external-priority patent/WO2016016366A1/en
Publication of JP2017522348A publication Critical patent/JP2017522348A/ja
Publication of JP2017522348A5 publication Critical patent/JP2017522348A5/ja
Application granted granted Critical
Publication of JP6599976B2 publication Critical patent/JP6599976B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017505221A 2014-07-31 2015-07-30 置換ジヒドロピリミジノン及び好中球エラスターゼ活性の阻害薬としてのそれらの使用 Active JP6599976B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14179289 2014-07-31
EP14179289.5 2014-07-31
PCT/EP2015/067504 WO2016016366A1 (en) 2014-07-31 2015-07-30 Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity

Publications (3)

Publication Number Publication Date
JP2017522348A JP2017522348A (ja) 2017-08-10
JP2017522348A5 true JP2017522348A5 (enExample) 2018-09-06
JP6599976B2 JP6599976B2 (ja) 2019-10-30

Family

ID=51257372

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017505221A Active JP6599976B2 (ja) 2014-07-31 2015-07-30 置換ジヒドロピリミジノン及び好中球エラスターゼ活性の阻害薬としてのそれらの使用

Country Status (4)

Country Link
US (1) US9290457B2 (enExample)
EP (1) EP3174860B1 (enExample)
JP (1) JP6599976B2 (enExample)
WO (1) WO2016016366A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI581838B (zh) * 2016-03-23 2017-05-11 國立清華大學 感測式護具內襯及其防護裝置
US10406751B2 (en) * 2017-04-14 2019-09-10 Desktop Metal, Inc. Automated de-powdering with level based nesting
AU2018346597B2 (en) 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
JP7449242B2 (ja) 2018-05-17 2024-03-13 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的ペプチダーゼ30(usp30)阻害剤として有用な縮合二環化合物
JP7530889B2 (ja) 2018-10-05 2024-08-08 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的プロテアーゼ30(usp30)阻害剤として作用する縮合ピロリン
JP7672641B2 (ja) 2019-09-17 2025-05-08 メレオ バイオファーマ 4 リミテッド 移植片拒絶反応、閉塞性細気管支炎症候群、及び移植片対宿主病の治療に使用するためのアルベレスタット
GB201918416D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
IL297211B2 (en) 2020-04-16 2025-12-01 Mereo Biopharma 4 Ltd Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
KR20240090272A (ko) 2021-10-20 2024-06-21 메레오 바이오파마 4 리미티드 섬유화 치료에 사용하기 위한 호중구 엘라스테이스 억제제
WO2026032210A1 (zh) * 2024-08-05 2026-02-12 上海壹迪生物技术有限公司 一种含嘧啶酮的化合物、其药物组合物及其用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60214428T2 (de) 2001-12-20 2007-09-20 Bayer Healthcare Ag 1, 4-dihydro-1, 4-diphenylpyridin-derivate
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
ES2293077T3 (es) 2002-08-27 2008-03-16 Bayer Healthcare Ag Derivados de dihidropiridinona como inhbidores de hne.
GB2392910A (en) * 2002-09-10 2004-03-17 Bayer Ag 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors
EP1546113B1 (en) 2002-09-10 2013-05-01 Bayer Intellectual Property GmbH Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes
WO2004024701A1 (en) 2002-09-10 2004-03-25 Bayer Healthcare Ag Heterocyclic derivatives
JP4825194B2 (ja) * 2004-02-26 2011-11-30 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 1,4−ジアリール−ジヒドロピリミジン−2−オン化合物およびヒト好中球エラスターゼ阻害剤としてのそれらの使用
ES2428503T3 (es) 2004-02-26 2013-11-08 Bayer Intellectual Property Gmbh 1,4-Diaril-dihidropirimidin-2-onas y su uso como inhibidores de elastasa de neutrófilos humanos
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
GB0512940D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Compounds and their use
WO2009013444A1 (en) 2007-07-25 2009-01-29 Argenta Discovery Limited Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
DE602007009095D1 (de) 2006-05-04 2010-10-21 Pulmagen Therapeutics Inflamma Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase
US8198288B2 (en) 2006-05-04 2012-06-12 Pulmagen Therapeutics (Inflammation) Limited Tetrahydropyrrolopyrimidinediones and their use in therapy
DE102006031314A1 (de) 2006-07-01 2008-01-03 Bayer Healthcare Aktiengesellschaft Verwendung von 1,4-Diaryl-dihydropyrimidin-2-on-Derivaten zur Behandlung der pulmonalen arteriellen Hyptertonie
US20100010024A1 (en) 2006-07-01 2010-01-14 Bayer Healthcare Ag Use of1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertension
WO2009037413A1 (en) 2007-09-19 2009-03-26 Argenta Discovery Limited Dimers of 5- [ (4-cyanophenyl) sulfinyl] -6-methyl-2-oxo-1- [3- (trifluoromethyl)phenyl] -1,2-dihydropyridine-3-carboxamide as inhibitors of human neutrophil elastase for treating respiratory diseases
WO2009060206A1 (en) 2007-11-07 2009-05-14 Argenta Discovery Limited 3,4,6,7-tetrahydro-1h-pyrrolo[3,4-d]pyrimidine-2,5-diones and their therapeutic use
GB0721866D0 (en) 2007-11-07 2007-12-19 Argenta Discovery Ltd Pharmaceutical compounds having dual activities
WO2009060158A1 (en) 2007-11-07 2009-05-14 Argenta Discovery Limited 4- (4-cyanophenyl) -1- (3-trifluoromethylphenyl) -3,4, 6, 7-tetrahydro-1h-pyrrolo [3, 4- d] pyrimidine-2, 5-dione derivatives and their use as human neutrophil elastase inhibitors
CN101903356B (zh) 2007-12-20 2013-05-22 拜耳知识产权有限责任公司 4-(4-氰基-2-硫代芳基)二氢嘧啶酮和它们的使用
DE102008022521A1 (de) 2008-05-07 2009-11-12 Bayer Schering Pharma Aktiengesellschaft 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung
DE102007061766A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung
DE102009004197A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung
DE102009016553A1 (de) 2009-04-06 2010-10-07 Bayer Schering Pharma Aktiengesellschaft Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung
GB201004179D0 (en) 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
GB201004178D0 (en) 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
JP2013177318A (ja) 2010-06-30 2013-09-09 Dainippon Sumitomo Pharma Co Ltd ジヒドロピリミジノン誘導体およびその医薬用途
CN104024241B (zh) 2011-08-01 2016-01-20 大日本住友制药株式会社 尿嘧啶衍生物和其用于医学目的的用途
CA2848557A1 (en) 2011-09-14 2013-03-21 Chiesi Farmaceutici S.P.A. Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhibitors
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity

Similar Documents

Publication Publication Date Title
JP2017522348A5 (enExample)
JP2017522350A5 (enExample)
JP2010516702A5 (enExample)
JP2019504898A5 (enExample)
JP2020526561A5 (enExample)
JP2014525426A5 (enExample)
JP2014511891A5 (enExample)
JP2014525427A5 (enExample)
JP2014525425A5 (enExample)
JP2019504899A5 (enExample)
RU2016115803A (ru) Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний
JP2014037426A5 (enExample)
JP2004529911A5 (enExample)
JP2017513932A5 (enExample)
JP2014530900A5 (enExample)
JP2017523225A5 (enExample)
JP2017522349A5 (enExample)
JP2017522352A5 (enExample)
JP2015520738A5 (enExample)
JP2009532417A5 (enExample)
JP2017526614A5 (enExample)
JP2012526769A5 (enExample)
JP2009543795A5 (enExample)
JP2016529306A5 (enExample)
JP2016510785A5 (enExample)